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Abstract
Background:  Breast cancer is the most common cancer in women in the U.S. and Western Europe.
Amplification of the her-2/neu gene occurs in approximately 25% of invasive ductal carcinomas of the breast. The
first HER-2/neu-targeted approach to reach the clinic was trastuzumab, a humanized monoclonal antibody
directed against the extracellular domain of the HER-2/neu protein. Trastuzumab therapy prolongs the survival
of patients with metastático HER-2/neu-overexpressing breast cancer when combined with chemotherapy and
has recently been demonstrated to lead to dramatic improvements in disease-free survival when used in the
adjuvant therapy setting in combination with or following chemotherapy. Here, we performed a meta-analysis of
completed clinical trials of adjuvant trastuzumab in the adjuvant setting. Survival, recurrence, brain metastases,
cardiotoxicity and directions for future research are discussed.
Methods:  A meta-analysis of randomized controlled trials (RCT) was performed comparing adjuvant
trastuzumab treatment for HER2-positive early breast cancer (EBC) to observation. The MEDLINE, EMBASE,
CANCERLIT and Cochrane Library databases, and abstracts published in the annual proceedings were
systematically searched for evidence. Relevant reports were reviewed by two reviewers independently and the
references from these reports were searched for additional trials, using guidelines set by QUOROM statement
criteria.
Results: Pooled results from that five randomized trials of adjuvant Trastuzumab showed a significant reduction
of mortality (p < 0.00001), recurrence (p < 0.00001), metastases rates (p < 0.00001) and second tumors other
than breast cancer (p = 0.007) as compared to no adjuvant Trastuzumab patients. There were more grade III or
IV cardiac toxicity after trastuzumab (203/4555 = 4.5%) versus no trastuzumab (86/4562 = 1.8%). The likelihood
of cardiac toxicity was 2.45-fold higher (95% CI 1.89 – 3.16) in trastuzumab arms, however that result was
associated with heterogeneity. The likelihood of brain metastases was 1.82-fold higher (95% CI 1.16 – 2.85) in
patients who received trastuzumab.
Conclusion: The results from this meta-analysis are sufficiently compelling to consider 1 year of adjuvant
trastuzumab treatment for women with HER-2-positive EBC based on the risk: benefit ratio demonstrated in
these studies. Adequate assessment of HER-2/neu status is critical, and careful cardiac monitoring is warranted
because of cardiac toxicity. Clinical trials should be designed to answer unsolved questions.
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Background
Breast cancer is the most common cancer in women in the
U.S. and Western Europe. More than 210,000 women
were predicted to be diagnosed, and more than 40,000
were predicted to die from the disease in 2005 in the U.S.
[1]. HER-2/neu belongs to a family of four transmem-
brane receptor tyrosine kinases that mediate cell growth,
differentiation, and survival [2,3]. Overexpression of the
HER-2/neu protein, amplification of the her-2/neu gene,
or both occurs in 20%–25% of breast cancers [4,5]. HER-
2/neu-positive breast cancer is an aggressive type that has
a high rate of recurrence and short disease-free intervals
after adjuvant (postoperative) chemotherapy [4]. Trastu-
zumab (Herceptin®; F. Hoffmann-La Roche Ltd., Basel,
Switzerland), a monoclonal antibody directed against
HER-2, improves survival and quality of life when given in
combination with taxanes as first-line therapy in women
with metastatic breast cancer [3-5] and has shown efficacy
as monotherapy [6,7]. We now have the results of five
large appropriately powered studies assessing the role of
trastuzumab in addition to adjuvant chemotherapy for
patients with HER2 positive tumours [5-7]. In this way,
our group investigated whether the administration of tras-
tuzumab was effective as adjuvant treatment for HER2-
positive breast cancer if used after completion of the pri-
mary treatment for reducer mortality, recurrence, metas-
tases and subsequent other tumors than breast cancer rate.
Also, the another objective the current review was to eval-
uate the incidence of cardiac toxicity and brain metastases
to give a more balanced view of the total evidence and to
increase statistical precision.
Methods
Purpose
To investigate whether the administration of trastuzumab
was effective as adjuvant treatment for HER2-positive
breast cancer if used after completion of the primary treat-
ment for mortality, recurrence, metastases and second
tumor no breast cancer rate. Also, the another objective
the current review was to evaluate the incidence of cardiac
toxicity and brain metastases to give a more balanced view
of the total evidence and to increase statistical precision.
Types of studies, participants, interventions and outcome 
measures
Published randomized controlled trials were eligible for
this metaanalysis. Published abstracts were included but
unpublished studies were not sought. Studies published
in any language were also eligible if they fulfilled the
inclusion criteria. No authors were contacted for clarifica-
tion or verification of patient data. All the trastuzumab
adjuvant trials enrolled patients with HER-2-positive
(immunohistochemistry 3+/fluorescence in situ hybridi-
zation positive or chromogenic in situ hybridization pos-
itive for FinHer) invasive breast cancer resected by
lumpectomy or mastectomy. Patients could have node
positive (all trials) or high-risk, node-negative (N9831,
HERA, BCIRG 006, Fin her) disease, and all patients were
to receive adjuvant chemotherapy and appropriate radio-
therapy and hormonal therapy. Patients were required to
have no locally advanced or distant disease and no previ-
ous or current cardiac disease. Trastuzumab administered
i.v. at any dose and for any time of duration in the adju-
vant setting. Differences in mortality, recurrence, Metas-
tases, brain metastases, second tumor non breast cancer
and cardiac toxicity rates (classified according to New
York Heart Association) were collected. Mortality was
defined as death from any cause, recurrence was defined
as recurrence of breast cancer at any site; Metastases was
defined as of the first distant tumor recurrence, ignoring
locoregional recurrences and second breast or non breast
cancers. Brain metastases were defined as recurrence in
CNS. The term "other tumors no breast cancer" was used
to define tumors that appeared after the treatment exclud-
ing new case of breast cancer or recurrences of that.
Search strategy for identification of studies
Medline and manual searches were done (completed
independently and in duplicate) to identify all published
(manuscripts and abstracts) randomized controlled trials
(RCTs) that comparing adjuvant trastuzumab treatment
for HER2-positive early breast cancer to observation. The
Medline search was done on PubMed between 1966 and
2006 with no language restrictions, using the search terms
"trastuzumab," breast cancer" or "metastases," adjuvant
trastuzumab" or "post operative traztusumab," and "her-
2 overexpression." The second search was done through
CancerLit, and the Cochrane Library to identify rand-
omized trials published between January 1998 and July
2006, using MeSH headings (trastuzumab, adjuvant tras-
tuzumab, her-2 over expression, breast cancer/sc {Sec-
ondary}, ex-lode Clinical Trials, clinical trial {publication
type}) and text words (breast, cancer, adjuvant:, trastuzu-
mab, trial, and study) without language restrictions. All
the searched abstracts were screened for relevance. Man-
ual searches were done by reviewing articles and abstracts
cited in the reference lists of identified RCTs, by reviewing
the first author's article, abstract file, from reference lists of
retrieved papers, textbooks and review articles. Also,
abstracts published in the Proceedings of the Annual
Meetings of the American Society of Clinical Oncology
(through 2005) were systematically searched for evidence
relevant to this meta analysis. The selection of studies for
inclusion was carried out independently by two of the
authors (V-GA and S-LA). Each study was evaluated for
quality using the scale of 1 to 5 proposed by Jadad [8]. If
reviewers disagreed on the quality scores, discrepancies
were identified and a consensus was reached. Trial data
abstraction was also done independently and in dupli-
cate, but abstractors were not blinded to the trials' authorsBMC Cancer 2007, 7:153 http://www.biomedcentral.com/1471-2407/7/153
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or institution. The reviewers were familiar with the trials,
and there were only five trials, so blinding the abstracts
was not practical. Any discrepancies in data abstraction
were examined further and resolved by consensus.
Analysis of the review
The data analyses were made with Review Manager Ver-
sion 4.2 provided by The Cochrane Collaboration. All
analyses were carried out on an intention-to-treat basis;
that is, all patients randomly assigned to a treatment
group were included in the analyses according to the
assigned treatment, irrespective of whether they received
the treatment or were excluded from analysis by the inves-
tigators. For categorical variables, weighted risk ratios and
their 95% confidence interval were calculated using Rev-
Man 4.2 software according to the Peto method [22].
Results were tested for heterogeneity at significance level
of P < 0.05 according to the methods outlined by Der
Simonian and Laird [23]. A fixed effects model was used
if there was no evidence of heterogeneity between studies,
if there was evidence of heterogeneity random effects
model was used for meta-analysis. The odds ratio and
95% confidence interval were calculated for each trial and
presented in a Forrest plot. Sensitivity analyses was per-
formed by excluding the trials which Jadad-scale was only
1 score. Publication bias is a common concern in meta-
analysis that is related to the tendency of journals to favor
the publication of large and positive studies. We chose a
commonly used method for detecting publication bias,
which is a graphical plot of estimates of the ORs from the
individual studies versus the inverse of their variances,
which is commonly referred to as a "funnel plot." An
asymmetry in the funnel would be expected if there was
publication bias with smaller studies tending to show
larger ORs, because small studies with no significant sta-
tistical results would be less likely to be reported.
Results
The two trial assessors agreed on the selection of five RCTs
[11-14]. The Quorum flow diagram illustrates the main
reasons for trial exclusion (Figure 1). Combining these tri-
als yielded data on 9117 patients. Four large, randomized,
clinical trials and one smaller randomized Finnish trial of
trastuzumab as adjuvant therapy for operable breast can-
cer have been completed and their initial results reported:
the Breast International Group (BIG) Herceptin® Adjuvant
(HERA) [12], Breast Cancer International Research Group
(BCIRG)-006 [13], the NSABP B-31 [11], Intergroup
N9831 [11], and Finnish FinHer trial [14] (Table 1). Two
arms of those studies were not included in this review.
One arm of the BIG HERA trial with 2-year of use of tras-
tuzumab with 1694 patients was excluded. Another arm
excluded was of the BCIRG-006 trial, which used
docetaxel and carboplatin plus trastuzumab (TCH) as
adjuvant systemic therapy. These arms of studies were
excluded because had not group controls in other studies
or in same them.
Description of studies
The designs of all four major adjuvant trastuzumab trials
and the smaller Fin Her study are summarized in Table 1
and 2. All the trastuzumab adjuvant trials enrolled
patients with HER-2-positive (immunohistochemistry
3+/fluorescence in situ hybridization positive or chro-
mogenic in situ hybridization positive for FinHer) inva-
sive breast cancer resected by lumpectomy or mastectomy.
Patients could have node positive (all trials) or high-risk,
node-negative (N9831, HERA, BCIRG 006, FinHer) dis-
ease, and all patients were to receive adjuvant chemother-
apy and appropriate radiotherapy and hormonal therapy.
In addition, patients were required to have no locally
advanced or distant disease and no previous or current
cardiac disease. Cardiac eligibility criteria differed
between the trials. The HERA trial required patients to
have a normal left ventricular ejection fraction (LVEF) ≥
55% (as measured by echocardiography or multiple-gated
acquisition [MUGA] scan) after completion of chemo-
therapy and radiotherapy, while in the B-31 and N9831
trials, baseline LVEF was required to be ≥ 50% after com-
pletion of chemotherapy. In the BCIRG 006 trial, baseline
LVEF was required to be ≥ 50% after surgery. Additional
The flowchart Figure 1
The flowchart. RT: radiotherapy; RCTs: randomized control-
led trials, EBCT: Early Breast conserving therapy.
1930 abstracts excluded 
Reasons: no randomization, no valid survival data, 
metastatic breast cancer included, or trastuzumab 
alone group, and review articles 
      1960    potentially eligible abstracts 
30 trials retrieved for detail 
25 trials excluded
Reasons: no adequate phase II 
diagnosis, no randomization, no final 
data of trials being pubished, metastático 
breast cancer included or retrospective 
design 
5 trials retrieved for detail 
No more trials were found according to the 
references of these articles 
5 RCTs included at last BMC Cancer 2007, 7:153 http://www.biomedcentral.com/1471-2407/7/153
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cardiac exclusion criteria included a history of myocardial
infarction, congestive heart failure (CHF), coronary artery
disease, angina pectoris requiring medication, uncon-
trolled hypertension, clinically significant valvular dis-
ease, or unstable arrhythmias.
NSABP-31 and N9831
The NSABP B-31 trial [11] compared four cycles of doxo-
rubicin and cyclophosphamide (AC) followed by four
cycles of every-3-week paclitaxel (P) (AC.P, arm1) with
AC.P plus 52 weeks of trastuzumab (H) beginning with
the first cycle of P (arm 2). The N9831 trial [11,13] was a
three-arm study that compared four cycles of AC followed
by 12 weekly doses of paclitaxel (AC.P, arm A) with AC.P
followed by 52 weeks of H beginning after P (arm B) and
with AC.P plus 52 weeks of H beginning with the first P
cycle (arm C). Because arm 1 and arm 2 of the B-31 trial
are similar to arms A and C of the N9831 trial, the studies
were amended to include a joint statistical analysis com-
bining arm 1 and arm A for comparison with arm 2 and
arm C. Arm B was excluded from the analysis because H
was not given concurrently with P. In both trials, only
patients with tumors scored as with 3+ or more staining
for HER2 by immunohistochemistry (IHC) or gene
amplification by fluorescence in situ hybridization (FISH)
were eligible. HER2 testing was centrally confirmed or
performed in approved reference laboratories. In an
intent-to treat analysis with a combined median follow-
up of two years (2.4 years for B-31 and 1.5 years for N-
9831), there was a highly significant 52 percent reduction
in the risk of disease recurrence with sequential trastuzu-
mab (three-year DFS 87 versus 75 percent, HR 0.48), and
despite the short follow-up, a 33 percent reduction in the
risk of death (three-year OS 94.3 versus 91.7 percent, HR
0.67) [11].
Fin her
Patients enrolled in the smaller FinHer trial were rand-
omized to three cycles of docetaxel or vinorelbine fol-
lowed by three cycles of fluorouracil, epirubicin, and
cyclophosphamide [14]. The primary aim of that trial was
to compare treatment using docetaxel with treatment
using vinorelbine. The subset of women with HER-2-pos-
itive tumors (n = 232) was further randomized to either
receive or not receive trastuzumab for 9 weeks together
with the first three cycles of docetaxel or vinorelbine [14].
The primary end point of FinHer was recurrence-free sur-
vival; secondary end points included adverse events (AEs),
the effect of treatment on LVEF, time to distant recurrence,
and overall survival [14]. Within this subgroup, DFS was
significantly better among those who received trastuzu-
mab (89 versus 78 percent, p = 0.01) and there was a trend
toward better OS (96 versus 90 percent, p = 0.07). The
magnitude of those benefits is similar to those seen in the
other trastuzumab trials that used one or two years of
treatment.
HERA
The HERA trial [12] was an international, multicenter,
randomized, controlled trial comparing 1 year or 2 years
of trastuzumab given every 3 weeks with observation (no
trastuzumab) in patients with HER-2/neu-positive early
breast cancer who had completed locoregional therapy
and at least four cycles of neoadjuvant or adjuvant chem-
otherapy from a list of approved regimens. Data were
available for 1,694 patients assigned to 2 years of treat-
ment with trastuzumab, 1,694 patients assigned to 1 year
of trastuzumab, and 1,693 patients assigned to observa-
tion. The results of 1 year of trastuzumab versus observa-
tion (first planned interim analysis) were recently
reported (n = 3,387) [12]. The most recent report included
1698 controls and 1703 patients treated with one year of
trastuzumab, who were followed for an average of 24
months [12]. There was a statistically significant 36 per-
cent reduction in disease recurrence (HR 0.64, three-year
DFS of 81 versus 74 percent) as well as a significant
improvement in overall survival (HR 0.66, 92 versus 90
percent in the trastuzumab and nontrastuzumab groups,
respectively). There were twice as many grade 3 or 4
adverse events with trastuzumab (11 versus 6 percent).
The only death attributed to cardiac causes was in the con-
trol arm. Trastuzumab was discontinued by 72 women (4
percent) because of cardiac problems.
Table 1: Summary of patient characteristics from the 
trastuzumab adjuvant trials
Characteristic 
(%)
BCIRG006 NSABP/N9831 HERA FIN HER
Median age 49 50 49 51
Age<50 years 52 51 51 51
Diameter primary 
tumor (%)
Tumor >= 20 mm 58 59.6 48.5 64.5
Estrogen receptor 
status (%)
Positive 56 52.2 54.5 47
Negative 44 47.6 45.5 53
Progesterone 
receptor status (%)
Positive 38 40.3 48.5 34
Negative 62 59.3 61.5 66
Node negative 
disease
29 5.7 32 16
Grade III tumor NA 69 60 65
Planed endocrine 
therapy
54 52 46 -
Taxane based 
chemotherapy
100 100 26 50
Quality trials by 
jadad scale
44 4 4BMC Cancer 2007, 7:153 http://www.biomedcentral.com/1471-2407/7/153
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BCIRG 006
The BCIRG-006 trial [13] was limited to patients whose
tumors had evidence of her-2/neu gene amplification
using FISH and included both node-positive and node
negative patients. This study evaluated the efficacy and
safety of three regimens as adjuvant systemic therapy after
surgery: (1) doxorubicin and cyclophosphamide followed
by trastuzumab plus docetaxel chemotherapy (AC.TH),
(2) docetaxel and carboplatin plus trastuzumab (TCH),
and (3) AC followed by docetaxel alone (AC.T) as the con-
trol arm. The results of a planned interim analysis of
3,222 patients after approximately one third of the
required number of relapses had occurred were recently
presented [13]. In a preliminary report with 23 month
median follow-up, DFS was significantly better in both
trastuzumab arms as compared to AC followed by
docetaxel (hazard ratio for DFS 0.49 and 0.61 for AC/
docetaxel/trastuzumab and TCH, respectively) [13]. There
was no significant difference between the two trastuzu-
mab-containing arms. However, the absolute benefit in
DFS from an anthracycline plus trastuzumab compared to
TCH was 4 percent. There were fewer symptomatic cardiac
events and a lower incidence of asymptomatic LVEF
decline with TCH compared to either anthracycline group
in terms of two endpoints.
Methodological quality of included studies
Each published randomized trial reported was assessed
for quality using the validated scale developed by Jadad et
al [8]. All the studies included were randomized. All stud-
ies reported the randomization procedure. The quality
scores of included studies are summarized in the table of
characteristics, Table 1.
Overall mortality
All the studies reported overall survival as one of the out-
comes. Altogether, the analyses included 5 trials with
9117 patients. The overall mortality rates was decreased
for trastuzumab arm (217/4555 = 6%) compared to no
trastuzumab arms (392/4562 = 8.5%). The individual
odds ratios ranged from 0.44 to 0.78 with a pooled odds
ratio for all of the trials of 0.52 with a 95% confidence
interval of 0.44 to 0.62. The test for heterogeneity was not
statistically significant with p value 0.28, which indicates
that the pooling of the data was valid. The overall odds
ratio suggests that there is difference between trastuzumab
arms and no trastuzumab arms in terms of overall mortal-
ity rate with p value <0.0001. Trastuzumab arms were
superior to no trastuzumab in decreased mortality rate in
5 studies, reaching statistical significance in 3 RCTs
[11,13], (Figure 2).
Table 2: Summary of cardiac safety with trastuzumab in early breast cancer
TRIAL ARM Baseline LEVF(%) CHF(%) Cardiac death Cardiac follow-up
HERA NIL >= 55 0 1 MUGA scan or echocardiogram at 3–4 wks prior 
to randomization, and 3, 6, 12, 18, 24, 30, 36, and 
60 mos from randomization
H 1 YEAR 0.6 0
NSABP-31 AC followed P >= 50 0.8 1 MUGA scan or echocardiogram 3 wks after last 
AC dose, 6, 9, and 18 mos from randomization, 
and 3 mos after last trastuzumab dose
AC followed PH 4.1 0
NCCTGN9831 AC followed P >= 50 0.3 1 MUGA scan 3 wks after last AC dose, 6 and 9 
mos from randomization, and 3 mos after the last 
trastuzumab dose
AC followed P and H 2.5 1
AC followed PH 3.5 0
BCIRG006 AC followed D >= 50 0.3 0 After last AC dose, after second docetaxel dose, 
after end of chemotherapy, and at 3, 12 and 36 
mos from randomization. At baseline, at 6 wks, 
4.5 mos,13.5 mos, and 37.5 mos from 
randomization
AC followed DH 1.6 0
DCarbo followed H 0.4 0
FIN HER NO H >= 50 3 0 MUGA scan or echocardiogram before 
chemotherapy, after CEF, and 12 and 36 mos 
after completion of chemotherapy
H0 0
AC, doxorubicin plus cyclophosphamide; BCIRG, Breast Cancer International ;NCCTG, North Central Cancer Treatment Group; NSABP, 
National Surgical Adjuvant Breast and Bowel Project; P, paclitaxel. MUGA, multigated acquisition;Research Group; Carbo, carboplatin;CHF, 
congestive heart failure; cum, cumulative incidence; D, docetaxel; H, trastuzumab; HERA, Herceptin® Adjuvant; LVEF, left ventricular ejection 
fraction;BMC Cancer 2007, 7:153 http://www.biomedcentral.com/1471-2407/7/153
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Recurrence rate
Five studies [11-14] reported this outcome representing a
total of 9117 patients. The disease free survival rates were
8.2% (400/4555) and 15.3% (700/4562) for trastuzumab
arms and no trastuzumab arms, respectively. The individ-
ual odds ratios varied from 0.32 to 0, 68. The test for het-
erogeneity was not statistically significant (p = 0.36)
allowing the results to be pooled. The overall odds ratio
was 0, 53 (95% CI 0.46 – 0.60) which suggests that there
was difference for disease free survival between the trastu-
zumab and no trastuzumab arms for adjuvant systemic
therapy (Figure 3).
Cardiac toxicity
Five studies [11-14] had reported cardiac toxicity data and
9117 patients were included in the analysis. There were
more cardiacs toxicity grade III or IV after trastuzumab use
(203/4555 = 4.5%) compared to no trastuzumab (86/
4562 = 1.8%). The likelihood of cardiac toxicity was 2.45-
fold higher (95% CI 1.89 – 3.16) in trastuzumab arms
patients. Test for heterogeneity was significant with p
value of 0.001. Repeated analyses of the above end points
excluding the fin her patient's only or using random effect
did not alter the results and conclusion (Figure 4).
Metastases rates
Five studies [11-14] reported the metastases rates. Nine
thousand, one hundred and seventeen patients were ran-
domized in those five studies. The metastases rates for all
randomized patients were different; 6% (276/4555) for
trastuzumab patients and 10.8% (497/4562) for no tras-
tuzumab patients (p <0.00001). Tests for heterogeneity in
the analysis were not significant (p = 0.34) (Figure 5).
Brain metastases
Three studies with 6738 patients reported brain metas-
tases incidence rate. The likelihood of brain metastases
was 1.82-fold higher (95% CI 1.16 – 2.85) in trastuzumab
arms patients. Test for heterogeneity was not significant
with p value of 0.50. (Figure 6)
Recurrence rate of the adjuvant trastuzumab trials in early Breast Cancer Figure 3
Recurrence rate of the adjuvant trastuzumab trials in early Breast Cancer.
mortality rate of the adjuvant trastuzumab trials in early Breast Cancer Figure 2
mortality rate of the adjuvant trastuzumab trials in early Breast Cancer.BMC Cancer 2007, 7:153 http://www.biomedcentral.com/1471-2407/7/153
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Second non breast malignancy
Only three studies [11,12] reported the second non -
breast cancer malignancy, 6738 patients were randomized
in those three studies. The likelihood of subsequent other
tumors than breast cancer were 0.33-fold smaller (95% CI
0, 15 – 0.74) in trastuzumab arms patients. Test for heter-
ogeneity was not significant with p value of 0.16 (Figure
7).
Evaluation of publication bias
The funnel plot of the log ORs versus the inverse of their
variances of the individual studies is displayed in Figure 8.
The plot formed a very distinct funnel shape with the log
ORs evenly distributed around the meta-analysis OR
regardless of the study variance. Therefore, there was no
indication of an asymmetry in the study findings by the
variance or size of the studies and, thus, little evidence for
publication bias.
Discussion
Data from our meta-analyses confirm that the addition of
one year of trastuzumab to anthracycline and taxane-con-
taining adjuvant chemotherapy regimens provides sub-
stantial benefit for women with HER2-positive breast
cancer, both in terms of disease recurrence and survival.
The results from all of the trials incorporating one year of
trastuzumab into the adjuvant regimen demonstrate a sta-
tistically significant increase in the incidence of sympto-
matic cardiac dysfunction and asymptomatic decreases in
LVEF. Trastuzumab was first employed for metastatic
breast cancer (MBC). The activity and safety of trastuzu-
mab as a single agent were investigated in two phase II
clinical trials in women with HER2-overexpressing MBC
who had progressed after one or two chemotherapeutic
regimens [15,16]. The objective response rates were
11.6% and 15% in these two studies [15,16]. Cardiac dys-
function was the most common adverse event, occurring
in 5% of treated patients, many of whom had received
doxorubicin prior to trastuzumab. In a study that was con-
Metastases rate of the adjuvant trastuzumab trials in early Breast Cancer Figure 5
Metastases rate of the adjuvant trastuzumab trials in early Breast Cancer.
cardiac toxicity of the adjuvant trastuzumab trials in early Breast Cancer Figure 4
cardiac toxicity of the adjuvant trastuzumab trials in early Breast Cancer.BMC Cancer 2007, 7:153 http://www.biomedcentral.com/1471-2407/7/153
Page 8 of 11
(page number not for citation purposes)
ducted to investigate the efficacy and safety of trastuzu-
mab as a single agent in the first-line treatment of HER2-
overexpressing MBC, the response rate was 26% [17]. In
that randomized phase II trial of first-line treatment, the
patients were randomly assigned to one of two dose levels
of trastuzumab (4 mg/kg initially followed by 2 mg/kg
weekly, or 8 mg/kg to start, followed by 4 mg/kg weekly).
The overall RR was 35% for women with 3+immunohis-
tochemical (IHC) staining nearly double that reported for
the previously treated patients. On the other hand, the
overall RR was zero for those with 2+ IHC staining [17].
This study concluded that single agent trastuzumab was
active and well-tolerated as a first-line treatment for
women with MBC with HER2 3+ overexpression, deter-
mined by either IHC or gene amplification by FISH [17].
From these clinical trials, it has been shown that trastuzu-
mab administered as a single agent is both active and well
tolerated [15-17]. The trastuzumab adjuvant trials have
also provided valuable information on the efficacy and
safety of combining trastuzumab with specific standard
chemotherapy regimens. The NSABP B-31 and NCCTG
N9831 trials have shown that trastuzumab can be com-
bined with a standard AC-paclitaxel regimen, and the
BCIRG 006 trial has shown that trastuzumab can be com-
bined with a standard AC-docetaxel and a nonanthracy-
cline regimen. Furthermore, there was a significantly
longer overall survival time with 1 year of adjuvant Tras-
tuzumab in the BCIR 006, B-31, N9831 and a clear trend
in the other studies. Ours results based in these three and
others two large powered studies assessing the role of
Trastuzumab in addition to adjuvant chemotherapy for
patients with HER2 positive tumors in reduced the mor-
tality rate, recurrence and second tumors other that breast
cancer. Together, these data present a variety of effective
Trastuzumab-based treatment options for clinicians.
Brain metastases
Another question observed in our review was the high
incidence of brain metastases in patients who received
adjuvant Trastuzumab. The causes of these trends are
unknown. Bendell and colleagues [20] retrospectively
studied 122 women treated with trastuzumab alone or in
second non breast malignancy of the adjuvant trastuzumab trials in early Breast Cancer Figure 7
second non breast malignancy of the adjuvant trastuzumab trials in early Breast Cancer.
Brain metastases of the adjuvant trastuzumab trials in early Breast Cancer Figure 6
Brain metastases of the adjuvant trastuzumab trials in early Breast Cancer.BMC Cancer 2007, 7:153 http://www.biomedcentral.com/1471-2407/7/153
Page 9 of 11
(page number not for citation purposes)
combination with chemotherapy for Her-2-overexpress-
ing metastatic breast cancer. Based on a median follow-up
of 23 months, 34% of patients were diagnosed with CNS
metastases, well above historical rates. At the time of diag-
nosis of CNS metastasis, 50% of patients were responding
to therapy or had stable disease. That report was con-
firmed by the study of Clayton and colleagues [21] which
followed 93 metastatic breast cancer patients. Brain
metastases occurred in 25% of patients during a median
follow-up period of 10.8 months from the start of trastu-
zumab therapy. One theory suggests that Her-2 overex-
pression endows tumor cells with increased metastatic
aggressiveness to sites such as the lungs and may similarly
augment metastatic propensity to the CNS [22,23]. Sec-
ond, by allowing patients to live longer, trastuzumab may
allow micrometastatic brain metastases to become symp-
tomatic as a natural consequence of an extended life span.
A nonexclusive, third theory posits that trastuzumab is
effective against systemic metastases but relatively ineffec-
tive against CNS metastases due to its poor penetration of
the blood-brain- barrier. That hypothesis may extend to
cytotoxic chemotherapy as well as Trastuzumab [24]. Lim-
ited pharmacokinetic data in support of this hypothesis
suggest that systemic administration of trastuzumab
results in drug levels in the CSF that are 300-fold lower
than in the serum [25]. Also, intrathecal administration of
4D5, the murine precursor of trastuzumab, shows efficacy
against a human xenograft of Her-2-overexpressing cancer
growing in the leptomeninges, suggesting that trastuzu-
mab could be efficacious if it could penetrate the blood-
brain- barrier [26]. Based on our data and other studies
[20,21] we predict that brain metastases will become
more prevalent as greater control over systemic metastases
is achieved, particularly with regard to Her-2-positive
tumors.
Cardiac toxicity
The incidence of cardiac events with trastuzumab in the
EBC setting remained at an acceptable level and was sim-
ilar across the adjuvant trials, with a reported overall inci-
dence that was 0.6%–3.3% higher [11-14]. Our results
analyzing 9117 patients submitted to adjuvant trastuzu-
mab by breast cancer suggest that sequencing the combi-
nation of trastuzumab and taxanes plus anthracycline-
based chemotherapy increases the risk for class III or IV
CHF (OR = 2.45, CI 95 1.89–3.16) However, in our anal-
yses that result was associated with heterogeneity using
random effect. Probably due to different definitions of
cardiac events, evaluations for cardiac safety, analysis of
cardiac end points, and duration of follow-up differed
among the adjuvant trials and thus make comprehensive
cross-trial conclusions difficult, as showed in Table 2.
Comparisons regarding cardiac safety should therefore be
approached with caution. Increasing evidence suggests
that, in patients with metastatic breast cancer who experi-
ence a significant LVEF decline, management with beta-
blockade and angiotensin-converting enzyme inhibition
may allow careful reinitiation of trastuzumab therapy
after assessment of the risk-benefit ratio [27]. In the B-31
trial, 27 of the 31 patients in the trastuzumab arm have
been followed for>6 months after diagnosis of a cardiac
event; 26 were asymptomatic at last assessment and 18
remained on cardiac medication [11]. In this way, the car-
diac function of all patients who start treatment with tras-
tuzumab should be monitored and with further follow-
up, it will become clearer whether sequential or anthracy-
cline-free regimens carry a lower risk of cardiac toxicity
with equivalent efficacy. The mechanism of cardiac dys-
function associated with trastuzumab is not clearly under-
stood, although several hypotheses have been proposed.
These include the modification of anthracycline-induced
cardiotoxicity, immunemediated destruction of cardio-
myocytes, the effects on HER2 signaling pathways that are
required for the maintenance of normal cardiac contractil-
ity, and the dependence on HER2 for myocyte survival,
which is then impaired during trastuzumab treatment
[27]. There is increasing experimental evidence support-
ing a direct toxic effect of HER2 blockade on the heart.
HER2 signaling appears to play an important role in
embryonic cardiac development and cardioprotection, at
least in rodents [28,29]. Those data suggest that trastuzu-
mab-related cardiotoxicity is not immune-mediated or
due to effects outside the heart, and it does not result
solely from the modification of anthracycline-induced
cardiac toxicity. In contrast to anthracycline-related cardi-
otoxicity, trastuzumab-associated toxicity does not appear
to be dose related, and it usually responds to standard
medical treatment or the discontinuation of trastuzumab
[30,31]. Thus, in the adjuvant setting, continued treat-
ment with trastuzumab is contraindicated if there is any
evidence of cardiac dysfunction, and monitoring for early
funnel plot for mortality rate in adjuvant trastuzumab trials Figure 8
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evidence of left ventricular dysfunction is important. In
contrast, continuation of trastuzumab therapy or resump-
tion of treatment after resolution of cardiac abnormalities
may be safe in some women with metastatic breast cancer
who develop early evidence of cardiac dysfunction.
Unresolved questions
The optimal timing of initiation of trastuzumab in
patients with early-stage HER-2/neu-positive breast cancer
who have completed adjuvant chemotherapy also has not
been defined. The HERA trial allowed patients to begin
trastuzumab up to 6 months after local treatment and
chemotherapy had been completed. Whether trastuzu-
mab would benefit patients who have completed chemo-
therapy >6 months previously is unknown. However, in
patients with HER-2/neu-positive breast cancer treated
with AC followed by paclitaxel chemotherapy, the hazard
rate for recurrence increased significantly the first year and
remained high in the second year after surgery. This would
suggest that trastuzumab therapy is beneficial, although
this situation has not been tested in randomized clinical
trials. While the sequential administration of trastuzumab
after chemotherapy appears to be effective, longer follow-
up is needed to determine whether simultaneous and
sequential administration with other chemotherapy
agents are equally effective and whether there is a popula-
tion of patients in whom chemotherapy is not necessary
(patients with estrogen receptor-positive and HER-2/neu-
positive disease, patients with negative lymph nodes and
tumors < 1 cm) and for whom trastuzumab alone might
represent appropriate adjuvant therapy. Patients in the
NSABP B-31, N9831, and BCIRG-006 trials received adju-
vant radiation upon completion of chemotherapy during
maintenance trastuzumab. Clinical trials should be
designed to answer those questions.
Limitations of our study
One limitation in our study is the data source extracted
from abstracted data or published studies and not individ-
ual patient data (IPD). Meta-analyses based on published
data tend to overestimate treatment effects compared with
individual patient data analyses. However, analyses using
individual patient data may include fewer studies if all
authors do not agree to submit their full databases to the
analyzing group. In general, an IPD-based meta-analysis
would give a more robust estimation for the association;
therefore, we should interpret the results with care, espe-
cially for a positive result. Although the risk of publication
bias exists in any meta-analysis, whether based on indi-
vidual patient data or not, we feel that this was not an
important aspect of our study, as many positive and neg-
ative trials were included in the analysis.
Conclusion
The results of this metanalysis indicate that the addition
of at least one year of trastuzumab to anthracycline and
taxane-containing chemotherapy provides substantial
benefit for women with HER2-positive breast cancer, both
in terms of disease recurrence and survival. Trastuzumab
has been approved for use in the adjuvant setting in the
United States for women with node-positive, HER2-over-
expressing breast cancer as part of a treatment regimen
containing doxorubicin, cyclophosphamide, and paclit-
axel. Although the data are insufficient to conclude
whether sequential or concurrent administration is supe-
rior, cardiac toxicity may be worse with the concurrent
approach. Despite close monitoring and aggressive man-
agement, combined treatment is associated with a small
but real increase in the risk of myocardial dysfunction. In
this way, patients must be screened for heart function
before, during trastuzumab therapy and the risk of cardi-
otoxicity must be balanced against the poor prognosis of
women with HER2-positive node-positive breast cancer.
Adequate assessment of HER-2/neu status is critical, and
clinical trials should be designed to answer unsolved
questions.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
VG carried out the search, acquisition and interpretation
of the data in studies. He also drafted the manuscript. VG
performed the statistical analysis and drafted the manu-
script. S LA participated in the design of the study; SE car-
ried out the search for articles and gave final approval of
the version to be published. and S FV participated in the
design of the study; D LI gave final approval of the version
to be published. All authors read and approved the final
manuscript.
Acknowledgements
The authors thank Cochrane Collaboration by provide the software 
Review Manager used in this review. We also thank all patients who had 
been treated in these trials.
References
1. Jemal A, Murray T, Ward E: Cancer statistics, 2005.  CA Cancer J
Clin 2005, 55:10-30.
2. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling net-
work.  Nat Rev Mol Cell Biol 2001, 2:127-137.
3. Gschwind A, Fischer OM, Ullrich A: The discovery of receptor
tyrosine kinases: targets for cancer therapy.  Nat Rev Cancer
2004, 4:361-370.
4. Slamon DJ, Clark GM, Wong SG: Human breast cancer: correla-
tion of relapse and survival with amplification of the HER-2/
neu oncogene.  Science 1987, 235:177-182.
5. Slamon DJ, Godolphin W, Jones LA: Studies of the HER-2/neu
protooncogene in human breast and ovarian cancer.  Science
1989, 244:707-712.
6. Ring AE, Ellis PA: Taxanes in the treatment of early breast can-
cer.  Cancer Treat Rev 2005, 31:618-627.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2007, 7:153 http://www.biomedcentral.com/1471-2407/7/153
Page 11 of 11
(page number not for citation purposes)
7. Vogel CL, Cobleigh MA, Tripathy D: Efficacy and safety of trastu-
zumab as a single agent in first-line treatment of HER2-over-
expressing metastatic breast cancer.  J Clin Oncol 2002,
20:719-726.
8. Jadad AR, Moore RA, Carroll D: Assessing the quality of reports
of randomized clinical trials: is blinding necessary?  Control Clin
Trials 1996, 7:1-12.
9. Clarke M, Oxman AD, eds: Analysing and presenting results.
The Cochrane Reviewers Handbook, 4.1 [updated January
2003], Section 8.  In The Cochrane Library Issue 1 Oxford: Update
Software; 2003. 
10. DerSimonian R, Laird N: Meta-analysis in clinical trials.  Control
Clin Trials 1986, 7:177-188.
11. Romond EH, Perez EA, Bryant J: Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer.  N
Engl J Med 2005, 353:1673-1684.
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B: Trastuzumab
after adjuvant chemotherapy in HER2-positive breast can-
cer.  N Engl J Med 2005, 353:1659-1672.
13. Slamon D, Eiermann W, Robert N: Phase III randomized trial
comparing doxorubicin and cyclophosphamide followed by
docetaxel (ACT) with oxorubicin and cyclophosphamide fol-
lowed by docetaxel and trastuzumab (AC TH) with
docetaxel, carboplatin and Trastuzumab (TCH) in HER2
positive early breast cancer patients: BCIRG 006 study.
Breast Cancer Res Treat 2005, 94(suppl 1):S5a.
14. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P: Adjuvant docetaxel
or vinorelbine with or without trastuzumab for breast can-
cer.  N Engl J Med 2006, 354:809-820.
15. Baselga J, Tripathy D, Mendelsohn J: Phase II study of weekly
intravenous recombinant humanized anti-p185HER2 mono-
clonal antibody in patients with HER2/neu-overexpressing
metastatic breast cancer.  J Clin Oncol 1996, 14:737-744.
16. Cobleigh MA, Vogel CL, Tripathy D: Multinational study of the
efficacy and safety of humanized anti-HER2 monoclonal anti-
body in women who have HER2-overexpressing metastatic
breast cancer that has progressed after chemotherapy for
metastatic disease.  J Clin Oncol 1999, 17:2639-2648.
17. Vogel CL, Cobleigh MA, Tripathy D: Efficacy and safety of trastu-
zumab as a single agent in first-line treatment of HER2-over-
expressing metastatic breast cancer.  J Clin Oncol 2002,
20:719-726.
18. Ross JS, Fletcher JA, Linette GP: The Her-2/neu gene and protein
in breast cancer 2003: biomarker and target of therapy.
Oncologist 2003, 8:307-25.
19. Press MF, Sauter G, Bernstein L: Diagnostic evaluation of HER-2
as a molecular target: an assessment of accuracy and repro-
ducibility of laboratory testing in large, prospective, rand-
omized clinical trials.  Clin Cancer Res 2005, 11:6598-607.
20. Bendell J, Domchek S, Burstein H, Harris L, Younger J, Kuter I, Bun-
nell C, Rue M, Gelman R, Winer E: Central nervous system
metastases in women who receive trastuzumab-based ther-
apy for metastatic breast carcinoma.  Cancer 2003,
97:2972-2977.
21. Clayton A, Danson S, Jolly S, Ryder W, Burt P, Stewart A, Wilkinson
P, Welch R, Magee B, Wilson G, Howell A, Wardley A: Incidence of
cerebral metastases in patients treated with trastuzumab
for metastatic breast cancer.  Br J Cancer 2004, 91:639-643.
22. Yu D, Hung M-C: Expression of activated rat neu oncogene is
sufficient to induce experimental metastasis in 3T3 cells.
Oncogene 1991, 6:1991-1996.
23. Lin N, Bellon J, Winer E: CNS metastases in breast cancer.  J Clin
Oncol 2004, 22:3608-3617.
24. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC: c-erb-
2/neu overexpression enhances metastatic potential of
human lung cancer cells by induction of metastasis-associ-
ated properties.  Cancer Res 1994, 54:3260-3266.
25. Pestalozzi B, Brignoli S: Traztuzumab in CSF.  J Clin Oncol 2000,
18:2350-2351.
26. Bergman I, Barmada M, Griffin J, Slamon D: Treatment of menin-
geal breast cancer xenografts in the rat using an Anti-P185/
HER2 antibody.  Clin Cancer Res 2001, 7:2050-2056.
27. Theodoulou M, Campos SM, Batist G: TLC D99 (D, Myocet) and
Herceptin (H) is safe in advanced breast cancer (ABC): final
cardiac safety and efficacy analysis.  Proc Am Soc Clin Oncol 2002,
21:55a.
28. Grote TH, Pineda LF, Figlin RA: Oral dolasetron mesylate in
patients receiving moderately emetogenic platinumcontain-
ing chemotherapy. Oral Dolasetron Dose Response Study
Group.  Cancer J Sci Am 1997, 3:45-51.
29. Erickson SL, O'Shea KS, Ghaboosi N: ErbB3 is required for nor-
mal cerebellar and cardiac development: a comparison with
ErbB2- and heregulin-deficient mice.  Development 1997,
124:4999-5011.
30. Keefe DL: Trastuzumab-associated cardiotoxicity.  Cancer
2002, 95:1592-1600.
31. Seidman A, Hudis C, Pierri MK: Cardiac dysfunction in the tras-
tuzumab clinical trials experience.  J Clin Oncol 2002,
20:1215-1221.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/7/153/pre
pub